Sinomenine has been used as an antirheumatic drug in China. Glucocorticoid combined with sinomenine could be an alternative therapeutic approach. In this study, we evaluated the sinomenine potential effect on glucocorticoid pharmacodynamics in vitro using a human peripheral blood mononuclear cell (PBMC) culture system.
concentration of many lipophilic drugs and thus leading to glucocorticoid (GC) resistant (Garcia-Carrasco et al., 2015) . Persistent expression of P-gp was identified on human peripheral blood lymphocytes (PBMCs) of GC resistant patients with systemic lupus erythematosus (Kansal, Tripathi, Rai, & Agarwal, 2016) . GC resistant RA patients also companied with higher percentage of P-gp expression (Maillefert et al., 1996) . SN was reported to down-regulate P-gp expression and inhibit the efflux function of P-gp in multidrug resistant bladder cancer cell model 253 J/DOX (Chen et al., 2014) . Whether therapeutic dose of SN can suppress the function of P-gp in PBMCs, to potentiate immunosuppressive effect of GC is essential to be clarified.
An immune-cell culture system in vitro using the mitogen-activated PBMCs appeared to be able to simulate the immune network in vivo (Xu, Meng, Kusano, et al., 2017; Xu, Meng, Tu, et al., 2017) .
Hence, in the present study, we evaluated the potential additive effect of SN on GC pharmacodynamics in vitro to suppress the proliferation of T-cell mitogen activated PBMCs with a focus on P-gp function.
GCs mediate their effects by binding on the glucocorticoid receptor (GR), an intracellular hormone receptor, which in absence of a stimulus remain inactive in the cytoplasm. After GC binding, GRs undergo conformational change and translocate into nucleus where they homodimerize and act as a transcriptional regulator of many target genes by binding on GC response elements. Consequently, the GC-GR homodimer shows strong anti-inflammatory and immunosuppressive potencies (Onda et al., 2006; Panagiotou, Mihailidou, Brauhli, Katsarou, & Moutsatsou, 2018) . To explain the additional effects of SN on GC pharmacodynamics, we investigated SN on GR expression levels and GR subcellular localization. Comparing with the T-cell mitogen activated PBMCs, human leukemic Jurkat T-cells were easier to obtain with higher established reliability and thus chosen for this investigation (Panagiotou et al., 2018) , in addition to PBMCs.
| MATERIALS AND METHODS

| Reagents
Roswell Park Memorial Institute (RPMI) 1640 and fetal bovine serum (FBS) were purchased from Gibco BRL (Grand Island, NY, United States). Concanavalin A was purchased from Seikagaku Kogyo Co., Tokyo, Japan. SN (purity: more than 98%, biological source: S. acutum) and verapamil were purchased from Sigma Aldrich (St. Louis, MO, United States). SN was dissolved in ethanol (Wako Pure Chemical Industries, Ltd., Japan) at a concentration of 15 mM, filtered through a 0.2 μm membrane filter (Advantec Co., Japan) then stored at 4°C until use. The working concentrations were prepared by dilution with ethanol. Methylprednisolone (MP) was provided from Sigma Aldrich (St. Louis, MO, United States), dissolved in ethanol, and then stored at 4°C until use. The cell proliferation WST-8 assay kits were obtained from Dojindo Molecular Technologies, Inc., Japan. FITC mouse antihuman CD4 and APC Mouse Anti-Human CD8 were obtained from BD Biosciences, San Jose, CA, United States. GR antibody (G-5) was provided by Santa Cruz Biotechnology, INC (dilution 1:1000, # sc-393232). β-actin was purchased from Proteintech Group (dilution 1:5000, # 66009-1-Ig). Anti-TATA binding p antibody was obtained from Abcam (dilution 1:1000, # ab818). All other reagents were of the highest quality available from commercial vendors.
| Subjects
The present study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).
The study was approved by the Ethical Committee of Tokyo University of Pharmacy and Life Sciences, and written informed consent was obtained from all healthy subjects included in the study. The study included seven healthy subjects (four males and three females with a mean age of 26.8 years). These subjects had neither a history of immunological disorders nor a history of taking immunosuppressive drugs including GC.
| Isolation and culture of PBMCs and evaluation of drug effects in vitro
Twenty milliliters of venous blood were taken from healthy subjects between 9:00 and 11:00 in the morning and heparinized. This 20 mL sample size was the smallest possible to examine the effects of MP in the presence or absence of SN. The heparinized blood was loaded on 4 mL of Ficoll-Hypaque (Nakarai Co., Japan), and centrifuged at 1,300 g for 20 min. PBMCs were separated and suspended with RPMI 1640 medium containing 10% FBS, 100,000 IU/L penicillin, and 100 mg/L streptomycin to a final density of 1 × 10 6 cells/mL as we described previously (Xu, Meng, Kusano, et al., 2017 (Xu, Meng, Tu, et al., 2017) .
| Functional assays for P-glycoprotein in PBMCs
PBMCs were loaded with a final concentration of 2 μM of Rhodamine 123 (Rh123) and incubated for 10 min in 5% CO 2 at 37°C. Verapamil was used as a P-gp specific competitive inhibitor. Then, Rh123-treated cells were resuspended in a Rh123-free complete media with or without 0.03, 0.3, 3, 30, or 300 μM SN, combining with or without 0.5 ng/ mL MP, 0.5 ng/mL MP, and 5 μM verapamil at 37°C for 180 min. After the efflux period, cells were washed twice with ice-cold PBS/10%FBS
and were then stained with FITC mouse anti-human CD4 and APC Mouse Anti-Human CD8. After staining, the cells were washed twice and then resuspended in PBS and kept on ice in the dark until analysis
by FACSCanto™ II as we described before (BD Biosciences, San Jose, CA) (Xu, Meng, Tu, et al., 2017 
| Immunofluorescence
In order to confirm the effect of SN on GR subcellular compartmental- scope (Biozero BZ-8000 Series, Keyence, Japan). Signals were quantified using ImageJ program as mentioned above. A same size area was selected and the signal was measured in each nucleus, giving the intensity in arbitrary unit. (Figures 2a and b) .
| Statistical analysis
3.3 | Effects of sinomenine in the presence methylprednisolone on GR expression level and GR subcellular localization of Jurkat cells
To further investigate the underlying mechanism of the additional effect of SN on GC, the GR expression levels and GR subcellular localization were evaluated. Nuclear and cytoplasmic extractions were subjected to Western blot analysis, respectively. As shown in Figure 3a However, the levels of GR expression in cytoplasm were not dramatically changed by MP and/or SN (Figure 3b ).
Subsequently, GR subcellular localization of Jurkat cells was analyzed by using the data of Figure 3a and 3b. As shown in Figure 3c , after 2 h treatment by MP, GR was translocated into nucleus, and thus, the ratio of GR distribution in nucleus and cytoplasm was changed by MP treatment. However the influences of SN in combination with MP on GR distribution were obvious, comparing with the MP alone. Therefore, the combination of MP and SN changed the ratio of GR distribution in nucleus and cytoplasm more strongly (p < 0.01).
3.4 | Effects of sinomenine alone on GR expression level and GR subcellular localization of Jurkat cells (Figures 3 and 4 ).
| Effects of sinomenine in the presence or absence of methylprednisolone on GR expression level and GR subcellular localization of PBMCs
To confirm the modulation effects of SN and MP on the GR translocation, PBMCs obtained from three healthy subjects were fractionated, and GR expression levels were detected by Western blot. . Cells were pretreated with sinomenine for 24 h and harvested in 2 h after methylprednisolone treatment. Nuclear protein extracts were normalized to TATA-binding protein (TBP) and cytoplasmic extracts to β-actin. Data represented the mean ± S.E.M. of seven independent experiments. Statistical analyses were performed using Bonferroni's multiple comparison tests, *p < 0.05, **p < 0.01, and ***p < 0.001, as compared with the control group, respectively procedure was chosen to examine the SN potential effect on GC immunosuppressive efficacy (Xu, Meng, Tu, et al., 2017) . SN at 0.03-3 μM tended to suppress the proliferation of PBMCs. The additional function of these concentrations of SN also tended to enhance the immunosuppressive efficacy of MP to decrease the IC 50 values (Figures 1a and b) . SN at ≥30 μM significantly inhibited the PBMC proliferation ( Figure 1a) ; meanwhile, the agent potentiated the GC pharmacodynamics significantly (Figure 1b) . Our findings in vitro may partially explain why GC combined with SN has been used for the treatment of RA patients in China, especially for those who were suffering from refractory RA.
A lot of studies reported that SN had anticancer function in breast and many other cancers due to its suppressive effects on cell proliferation and apoptosis promotion effects (Lu et al., 2013; Some GC-resistant refractory RA patients were known to be accompanied with higher P-gp expression on peripheral lymphocytes (Maillefert et al., 1996) . Our data suggested that the additional function of SN to enhance GC immunosuppressive efficacy seemed not to be related with P-gp target of PBMCs because we did not observe the inhibitor capacity of SN (<300 μM) on the P-gp of Western blot analysis and densitometric quantification of total GR in nuclear (a) and cytoplasmic (b) extracts of Jurkat cells. Distribution of GR in nuclear/cytoplasmic fractions (c). Cells were pretreated with sinomenine for 24 h and methylprednisolone (MP) for 2 h. Nuclear protein extracts were normalized to TATA-binding protein (TBP) and cytoplasmic extracts to β-actin. Data represented the mean ± S.E.M. of seven independent experiments. Statistical analyses were performed using Bonferroni's multiple comparison tests, **p < 0.01 and ***p < 0.001, as compared with the control group, respectively obtain the similar results when using the human PBMC culture system, which suggested that P-gp inhibitory function of SN was a cell-type specific effect.
To elucidate the mechanism of the additional function of SN on Figure 6a were much weaker than those in Figure 3a and Figure 4a .
Low-to medium-dose GC had been shown to have not only antiinflammatory but also modifying properties in RA. However, numerous fears about GC adverse events such as osteoporosis, glucose intolerance, and cardiovascular disease had arisen in RA. In fact, these serious side effects might be largely related to high-dose GC treatment (Santiago & da Silva, 2014) . In contrast, two meta-analysis reports showed that SN alone or in combination with methotrexate was widely used for treating RA in China with better clinical efficiency and fewer adverse events (Chen, Huang, Huang, Chu, & Yan, 2015; Liu et al., 2016) . Due to the higher tolerability and safety combined with the results of the present research, SN might be a proper agent to maintain the low-dose GC immunosuppressive efficacy and thus decrease the incidence rate of GC adverse events.
In conclusion, our study provided strong evidence that plantderived alkaloid SN potentiates the GC pharmacodynamics significantly. However, the additional effect of SN had no relation to the FIGURE 6 Expression and subcellular localization of glucocorticoid receptor (GR) in peripheral blood mononuclear cells (PBMCs) after treatment with methylprednisolone (MP) and/or sinomenine (SN). Western blot analysis and densitometric quantification of total GR in nuclear (a) and cytoplasmic (b) extracts of PBMCs. Distribution of GR in nuclear/cytoplasmic fractions (c). Cells were pretreated with sinomenine for 24 h and harvested in 2 h after methylprednisolone treatment. Nuclear protein extracts were normalized to TATA-binding protein (TBP) and cytoplasmic extracts to β-actin. Data represented the mean ± S.E.M. of more than three experiments. Statistical analyses were performed using Dunnett's Multiple Comparison Test, *p < 0.05 as compared with the control group P-gp mediated efflux function because P-gp inhibitory function of SN was not observed in PBMC culture system. To disclose the underlying mechanism of SN actions, we found that SN itself regulates the GR translocation in both Jurkat T cells and normal human PBMCs, and the combination of SN and MP showed stronger GR-modulatory activity. These effects of SN were suggested to be beneficial for treatment of RA patients, and thus GC combined with SN would be an alternative and reasonable therapeutic approach for RA.
